Abstract 464P
Background
Brain metastasis occurs in about 50% of advanced HER2-positive BC patients. Moreover, there are still a lot of unresolved clinical issues, such as how to classify patients and adapt targeted therapy to better prolong survival.
Methods
The study recruited HER2-positive BCBM patients who attended the Fifth Medical Center of PLA General Hospital from 2003 to 2022. 32 HER2-positive BCBM patients treated between 2008 and 2022 at the First Hospital of Peking University and 43 HER2-positive BCBM patients from 2012 to 2022 at Xi'an Jiaotong University First Affiliated Hospital were included as an independent test set. All statistical methods and survival analyses were performed in SPSS 22.0 and R version 4.2.1.
Results
This study included 300 patients with HER2-positive BCBM. According to multi-factor analysis, the age, the number of brain metastases, radiotherapy after BCBM, and anti-HER2 therapy after BCBM were all independent factors influencing survival after diagnosis of BCBM. Different independent prognostic factors comprised the patient hierarchical evaluation model. Patients' warning scores range from 0 to 7. We divided the patients into three groups with obvious differences in prognosis: Low-risk (score≥1), median-risk group (score≥3), and high-risk group (score≥6). The patient prognosis was worse when the warning score was high. The results of the survival analysis showed significant differences between the three groups of patients (P<0.0001). The mean AUC values for 1-year, 2-year prognosis prediction was 0.69, 0.71, respectively. We acquired clinical data from 75 patients from other centers to further assess our model's generalization capabilities. Patients are categorized using the prognostic grading evaluation model, and prognostic analysis is performed (P<0.0001). The AUC values for 1-year, 2-year prognostic forecasts were 0.94. Patients in the median-risk group who received drug therapy combined with radiotherapy had significantly prolonged BMOS compared with the patients who received only drug therapy or radiotherapy (P=0.01).
Conclusions
A survival and prognostic stratification model was constructed based on the clinicopathological characteristics of a large cohort of HER2-positive BCBM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1301P - A prognostic clinical and circulating biomarker model to identify futile chemo-radiotherapy (CRT) in stage III NSCLC
Presenter: Rianne Vaes
Session: Poster session 04
1302P - Treatment outcomes and safety of durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in Thai populations: A real-world, multi-center observational study
Presenter: Piyada Sitthideatphaiboon
Session: Poster session 04
1303P - Immune-modulating effects on tumor draining lymph nodes following neoadjuvant chemoradiotherapy combined with immunotherapy in patients with T3-4N0-1 NSCLC
Presenter: Ezgi Ulas
Session: Poster session 04
1304P - A structured multidisciplinary approach for diagnosing immune-related pneumonitis in patients undergoing adjuvant durvalumab for stage III non-small cell lung cancer
Presenter: Illaa Smesseim
Session: Poster session 04
1305P - Importance of the resected lung tumor specimen in patients with locally advanced and metastatic non-small cell lung cancer undergoing prior targeted therapy
Presenter: Jeong Uk Lim
Session: Poster session 04
1307P - The Biocartis Idylla GeneFusion Assay (RUO) for lung cancer testing: The experience of testing over 5000 tumours in routine practice
Presenter: Lee Robertson
Session: Poster session 04
1308P - Diameter threshold for lung nodules at low-dose CT screening: Chinese population screening experience
Presenter: YE WENJUN
Session: Poster session 04
1309P - Immune exhaustion in tumor-free lymph nodes of non-small cell lung cancer (NSCLC) patients is associated with performance status and survival
Presenter: Laura Sellmer
Session: Poster session 04
1310P - Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes
Presenter: Xiwen Liu
Session: Poster session 04
1311P - Understanding the basis for intrinsic resistance to KRASG12C inhibitors
Presenter: Alba Santos Ramos
Session: Poster session 04